Management of Diabetic Peripheral Neuropathy.
10.3904/kjm.2015.89.3.277
- Author:
Myung Shin KANG
1
;
Chong Hwa KIM
Author Information
1. Department of Internal Medicine, Sejong General Hospital, Bucheon, Korea. drangelkr@hanmail.net
- Publication Type:Review
- Keywords:
Diabetes;
Diabetic neuropathy;
Treatment
- MeSH:
Anticonvulsants;
Anxiety;
Capsaicin;
Depression;
Diabetes Mellitus;
Diabetic Neuropathies;
Early Diagnosis;
Glucose;
Humans;
Membranes;
Neuralgia;
Pathology;
Peripheral Nervous System Diseases*;
Prevalence;
Risk Factors;
Serotonin;
Thioctic Acid
- From:Korean Journal of Medicine
2015;89(3):277-281
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus. The prevalence of neuropathic pain is estimated to occur in about 30-50% of all diabetic patients. Clinical symptoms vary depending on the nerves affected, and may include both positive and negative symptoms. Many patients with DPN experience pain or discomfort, anxiety, depression, and limitations in activity, which can significantly impact their physical, emotional, and social well-being. Early diagnosis is essential for the successful management of DPN. Routine management consists of glucose and risk factor control, and symptomatic relief, along with therapies designed to target the underlying disease pathology. Pharmacological treatment of DPN includes tricyclic compounds, serotonin noradrenalin reuptake inhibitors, the antioxidant alpha-lipoic acid, anticonvulsants, opiates, membrane stabilizers, topical capsaicin, and other drugs. Management of DPN must be tailored to each individual, and depends on a variety of factors, including disease severity and response to treatment.
